Fundraise

OSMUNDA raises ~$15M Series D to build device factory and AI platform

What's the deal? OSMUNDADealroom has a profile for this one. Try Dealroom →, a Chinese medical device contract research organisation (CRO) and services provider, has raised US$13.8M (≈$15 million) in a Series D round. The round was led by Zhejiang International Collaborative Innovation Investment.

What's the endgame? OSMUNDA offers clinical and regulatory services for medical devices, including clinical trials, global registration, biostatistics, training, and consulting. It plans to use the funds for a Marketing Authorisation Holder (MAH) manufacturing facility, proof-of-concept and pilot production sites, and a medical device AI platform with specialised models.

Why now? A new version of China's medical device Good Manufacturing Practice (GMP) rules takes effect in November 2026. The update clarifies quality management and supply-chain responsibilities for both MAHs and contract manufacturers.

Under the MAH system, research-focused firms can outsource production — but outsourcing does not remove quality liability. That tightens compliance demands while raising the value of specialised service platforms.

What could go wrong? OSMUNDA is expanding from clinical and registration work into manufacturing and digital tools. The disclosed information mostly covers how the money will be spent, which is not enough to prove returns from the AI business or new capacity.

The signal: The round reflects a bet that China's stricter device regulations will push demand toward integrated, compliant service providers. If OSMUNDA can turn clinical, regulatory, and production capabilities into reliable scale, it is positioned to claim a larger share.

Read more: itjuzi.com

Image credit: USDAgov

More top stories